Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate

Journal of Orthopaedic Research

Volumn 26, Issue 5, 2008, Pages 693-703

  Goodship, Allen E ^a   Blunn, Gordon W ^a   Green, Jonathan ^b   Coathup, Melanie J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aseptic loosening; Bone formation; Stress shielding; Total hip replacements; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; SODIUM CHLORIDE; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROUND REACTION FORCE; HIP PROSTHESIS; IN VIVO STUDY; NONHUMAN; OSTEOCYTE; OSTEOPENIA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTHESIS LOOSENING; SHEEP; STRESS STRAIN RELATIONSHIP; THERAPY EFFECT; THICKNESS; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT BEARING; ANIMAL; DRUG EFFECT; HIP; HIP ARTHROPLASTY; LOCOMOTION; MECHANICAL STRESS; METABOLIC BONE DISEASE; MICRORADIOGRAPHY; PATHOLOGY; PROSTHESIS FAILURE; RANDOMIZATION;

ANIMALS; ARTHROPLASTY, REPLACEMENT, HIP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMALE; HIP JOINT; IMIDAZOLES; LOCOMOTION; MICRORADIOGRAPHY; PROSTHESIS FAILURE; RANDOM ALLOCATION; SHEEP; STRESS, MECHANICAL;

EID: 43649096867     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20533     Document Type: Article

References (52)

1. Bellamy N, Buchanan WW, Goldsmith CH, et al. 1988. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833-1840.
2. Eisler T, Svensson O, Tengstrom A, et al. 2002. Patient expectation and satisfaction in revision total hip arthroplasty. J Arthroplasty 17:457-462.
3. Fumes O, Lie SA, Espehaug B. 2001. Hip disease and the prognosis of total hip replacements reported to the Norwegian Arthroplasty Register 1987-99. J Bone Joint Surg [Br] 83:579-586.
4. Older J. 2002. Charnley low-friction arthroplasty: a worldwide retrospective review at 15 to 20 years. J Arthroplasty 17:675-680.
5. Kuster MS. 2002. Exercise recommendations after total joint replacement: a review of current literature and proposal of scientifically based guidelines. Sports Med 32: 433-445.
6. Seyler TM, Mont MA, Ragland PS. 2006. Sports activity after total hip and knee arthroplasty: specific recommendations concerning tennis. Sports Med 36:571-583.
7. Dixon T, Shaw M, Ebrahim S, et al. 2004. Trends in hip and knee joint replacement: socio-economic inequalities and projections of need. Ann Rheum Dis 63:825-830.
8. Birrell F, Johnell O, Silman A. 1999. Projecting the need for hip replacement over the next three decades: influence of changing demography and threshold for surgery. Ann Rheum Dis 58:569-572.
9. Sporer S, Paprosky W. 2004. Femoral fixation in the face of considerable bone loss: the use of modular stems. Clin Orthop 429:227-231.
10. Krishnanmurthy AB, MacDonald S, Paprosky WG. 1997. 5 to 13 year follow up study of cementless femoral components in revision surgery. J Arthroplasty 12:839-847.
11. Stauffer RN. 1982. A ten year follow up study of total hip replacements. With particular reference to roentgeno-graphic loosening of the components. J Bone Joint Surg 64A:983-992.
12. Shanbhag AS, Jacobs JJ, Giant TT, et al. 1994. Composition and morphology of wear debris in failed uncemented total hip replacements. J Bone Joint Surg 76B:60.
13. Sychterz CJ, Moon KH, Hashimoto I, et al. 1996. Wear of polyethylene cups in total hip arthroplasty. A study of specimens retrieved post mortem. J Bone Joint Surg 78A: 1193-1200.
14. Engh CA, Bobyn JD. 1988. The influence of stem size and extent of porous coating on femoral bone resorption after primary cementless hip arthroplasty. Clin Orthop 231:7-28.
15. Radin EL, Rubin CT, Thrasher EL, et al. 1982. Changes in the bone-cement interface after total hip replacement. An in vivo animal study. J Bone Joint Surg [Am] 64:1188-1200.
16. Lanyon LE, Paul IL, Rubin CT, et al. 1981. In vivo strain measurements from bone and prosthesis following total hip replacement. An experimental study in sheep. J Bone Joint Surg [Am] 63:989-1001.
17. Aldinger PR, Sabo D, Pritch M, et al. 2003. Pattern of periprosthetic bone remodelling around stable unce mented tapered hip stems: a prospective 84-month follow-up study and a median 156-month cross-sectional study with DXA. Calcif Tissue Int 73:115-121.
18. Munting E, Smitz P, Van Sante N, et al. 1997. Effect of stemless femoral implant for total hip arthroplasty in the bone mineral density of the proximal femur. A prospective longitudinal study. J Arthroplasty 12:373-379.
19. Haynes DR, Hay SJ, Roger SD, et al. 1997. Regulation of bone cells by particle-activated mononuclear phagocytes. J Bone Joint Surg [Br] 79:988-994.
20. Horowitz SM, Purdon MA. 1995. Mechanisms of cellular recruitment in aseptic loosening of prosthetic joint implants. Calcif Tissue Int 57:301-305.
21. Schmalzried TP, Kwong LM, Jasty M. 1992. The mecha nism of loosening of cemented acetabular components in total hip arthroplasty. Analysis of specimens retrieved at autopsy. Clin Orthop 274:60-78.
22. Schmalzried TP, Jasty M, Harris WH. 1992. Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. J Bone Joint Surg 74A:849-863.
23. Gatti D, Rossini M, Zamberlan N, et al. 1996. Effect of ageing on trabecular and compact bone components of proximal and ultradistal radius. Osteoporosis Int 6:355-360.
24. Goodship AE, Walker PC, McNally D, et al. 1994. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 5:S53-S55.
25. Langkamer VG, O'Doherty DM, Goodship AE. 1992. Orthop Trans. 17:240.
26. Dambrain R, Dhem A. 1984. Bone vitality in induced radionecrosis of the mandible estimated by osteocytic population counting. Strahlentherapie 160:39-344.
27. Warner JJ, Philip JH, Brodsky GL, et al. 1987. Studies of nontraumatic osteonecrosis. Manometric and histologic studies of the femoral head after chronic steroid treatment: an experimental study in rabbits. Clin Orthop Relat Res 225:128-140.
28. Humphreys S, Spencer JD, Tighe JR, et al. 1989. The femoral head in osteonecrosis. A quantitative study of osteocyte population. J Bone Joint Surg 71B:205-210.
29. Calder JD, Pearse MF, Revell PA. 2001. The extent of osteocyte death in the proximal femur of patients with osteonecrosis of the femoral head. J Bone Joint Surg 83: 419-422.
30. Wise LM, Waldman SD, Kasra M, et al. 2005. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int 77:367-375.
31. Bergh MS, Muir P, Markel MD. 2004. Femoral bone adaptation to unstable long-term cemented total hip arthroplasty in dogs. Vet Surg 33:238-245.
32. El-Warrak AD, Olmstead M, Apelt D. 2005. An animal model for interface tissue formation in cemented hip replacements. Vet Surg 33:495-504.
33. Astrand J, Aspenberg P. 2002. Systemic alendronate prevents resorption of necrotic bone during revascularisa-tion: a bone chamber study in rats. BMC Musculoskelet Disord 3:19.
34. Aspenberg P, Astrand J. 2002. Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop Scand 73:20-30.
35. Shanbhag AS. 2006. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 14:215-225.
36. Blunn GW, Wait ME. 1991. Remodelling of bone around intramedullary stems in growing patients. J Orthop Res 9: 809-819.
37. Shanbhag AS. 2006. Use of bisphosphonates to improve the durability of total joint replacements. 14:215-225.
38. Im G, Puskas B, Rubash H, et al. 2002. Bisphosphonates enhance osteoblast proliferation and maturation. Orthop Res Soc Trans p. 0064.
39. Sahni M, Guenther HL, Fleisch H, et al. 1993. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011.
40. Noble BS, Stevens H, Loveridge N, et al. 1997. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 20:273-282.
41. Plotkin LI, Weinstein RS, Parfitt AM, et al. 1999. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374.
42. O'Doherty DM, Butler SP, Goodship AE. 1995. Stress protection due to external fixation. J Biomech 28:575-586.
43. Tanzer M, Karabasz D, Krygier JJ, et al. 2005. Bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res 441:30-39.
44. Peter B, Gauthier O, Laïb S, et al. 2006. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A 76:133-143.
45. DiResta GR, Brown H, Aiken S, et al. 2006. Use of an absorbable membrane to position biologically inductive materials in the periprosthetic space of cemented joints. J Biomech 39:833-843.
46. Healey JH, Shannon F, Boland P, et al. 2003. PMMA to stabilise bone and deliver antineoplastic and antiresorp-tive agents. Clin Orthop Relat Res 415 (Suppl):S263-S75.
47. Engh CA Jr, Young AM, Engh CA Sr, et al. 2003. Clinical consequences of stress shielding after porous-coated total hip arthroplasty. Clin Orthop 417:157-156.
48. Astrand J, Aspenberg P. 2002. reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop Scand 73:24-30.
49. Reid IR, Brown TP, Burckhardt P, et al. 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:151-152.
50. Black DM, Delmas PD, Eastell R, et al. 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
51. Reid IR, Miller P, Lyles K, et al. 2005. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908.
52. Venesmaa PK, Kroger HP, Miettinen HJ, et al. 2001. Alendronate reduces periprosthetic bone loss after unce-mented primary total hip arthroplasty: a prospective randomised study. J Bone Miner Res 16:2126-2131.